Compare HMN & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HMN | GENB |
|---|---|---|
| Founded | 1945 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1996 | N/A |
| Metric | HMN | GENB |
|---|---|---|
| Price | $54.94 | $16.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $47.33 | $23.20 |
| AVG Volume (30 Days) | 291.8K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 57.26 | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $1,701,400,000.00 | N/A |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $3.41 | $16.58 |
| P/E Ratio | $54.12 | ★ N/A |
| Revenue Growth | ★ 6.66 | N/A |
| 52 Week Low | $40.04 | $11.00 |
| 52 Week High | $54.64 | $18.18 |
| Indicator | HMN | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 82.02 | 61.75 |
| Support Level | $41.94 | $11.73 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.27 | 1.22 |
| MACD | 0.42 | 0.18 |
| Stochastic Oscillator | 91.80 | 73.50 |
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.